Marincola to lead Kite’s cell therapy research; plus moves at T-knife, Applied Molecular Transport, Frequency and NexImmune
Kite Pharma Inc. hired Francesco Marincola as SVP and global head of cell therapy research, effective Feb. 1. Marincola joined the Gilead Sciences Inc. (NASDAQ:GILD) unit from Refuge Biotechnologies Inc., where he was president and CSO. Marincola was also a tenured investigator at NIH in 1990-2013, and spent 15 of the 23 years as chief of the infectious disease and immunogenetics section at the NIH Clinical Center.
T-knife GmbH hired Thomas Soloway as CEO and Camille Landis as CBO and CFO. Soloway succeeds founding CEO Elisa Kieback, who is now CTO at the company, which emerged from stealth in August with a transgenic mouse platform designed to generate human, high affinity TCRs to treat solid tumors. Soloway was EVP, COO at Audentes Therapeutics Inc., which Astellas Pharma Inc. (Tokyo:4503) acquired for about $3 billion. Landis was SVP, corporate development at Unity Biotechnology Inc. (NASDAQ:UBX). ...